MedTrace Logo

Accelerating Lung Cancer Diagnosis Through Liquid Biopsy

NCT04863924 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2025-12-18

No results posted yet for this study

Summary

This study will assess the utility of liquid biopsy to accelerate the time to treatment for patients with newly diagnosed advanced non-small cell lung cancer, compared to the conventional diagnostic pathway of molecular testing of tumour tissue after imaging and biopsy.

Conditions

Interventions

DIAGNOSTIC_TEST

Liquid Biopsy

All patients will have a liquid biopsy with ctDNA molecular profiling

Sponsors & Collaborators

  • Lung Health Foundation

    collaborator UNKNOWN

  • The Princess Margaret Cancer Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2023-07-25
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04863924 on ClinicalTrials.gov